Injectable BPC-157 often produces faster systemic effects, while oral administration may take longer due to partial degradation in the digestive tract
The addition of B12 may reduce severity, though individual responses vary
It has extensive clinical trial data FDA-approved for both weight loss and type 2 diabetes
doi:10.3389/fncel.2015.00003 Uribe PM, Hudson AM, Lockard G, et al
Less common reports include fatigue 1224 hours after dosing, injection-site redness, and brief flushing
Tirzepatide has been approved for T2D management - the mean HbA1c reduction in SURPASS programme ranged between 1.9 and 2.6% across the trials and 4069% of participants achieved 10% WL with the higher doses (10 and 15 mg), despite that there was no additional support for lifestyle intervention [16, 43]